{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T17:16:26Z","timestamp":1779124586480,"version":"3.51.4"},"reference-count":55,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T00:00:00Z","timestamp":1719273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Widespread use of immune checkpoint inhibitors (ICIs) in cancer treatment has led to an increase in the number of reported cases of immunotherapy-related endocrinopathies. This study aimed to analyze and compare human leukocyte antigen (HLA) signatures associated with ICI-induced type 1 diabetes (ICI-T1D) and isolated adrenocorticotropic hormone deficiency (ICI-IAD) in patients with both conditions.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>HLA signatures were examined for their frequencies of occurrence in 22 patients with ICI-T1D without concurrent IAD, including 16 patients from nationwide reports (ICI-T1D group) and 14 patients with ICI-IAD without concurrent T1D (ICI-IAD group). The HLA signatures were also compared for their respective frequencies in 11 patients with ICI-T1D and ICI-IAD, including eight from nationwide reports (ICI-T1D\/IAD group).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In the ICI-T1D group, HLA-DRB1*09:01-DQB1*03:03 and DQA1*03:02, which are in linkage disequilibrium with DRB1*09:01-DQB1*03:03 and DRB1*13:02-DQB1*06:04, were susceptible to ICI-T1D, whereas DRB1*15:02-DQB1*06:01 was protective against ICI-T1D. In the ICI-IAD group, DPB1*09:01, C*12:02-B*52:01, and DRB1*15:02-DRB1*06:01, which are in strong linkage disequilibrium, were associated with susceptibility to ICI-IAD. Moreover, DRB1*15:02-DRB1*06:01 was not detected in the ICI-T1D\/IAD group.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This study revealed specific HLA signatures associated with ICI-T1D and ICI-IAD. Moreover, HLA-DRB1*15:02-DRB1*06:01, an ICI-IAD-susceptible HLA haplotype, coincides with the ICI-T1D-protective HLA haplotype, suggesting that the presence of DRB1*15:02-DRB1*06:01 may protect against the co-occurrence of T1D in patients with ICI-IAD.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ejendo\/lvae081","type":"journal-article","created":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T18:09:02Z","timestamp":1719338942000},"page":"9-16","source":"Crossref","is-referenced-by-count":8,"title":["HLA investigation in ICI-induced T1D and isolated ACTH deficiency including meta-analysis"],"prefix":"10.1093","volume":"191","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9115-9591","authenticated-orcid":false,"given":"Mayo","family":"Ono","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Metabolism and Nephrology, Graduate School of Medicine, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mototsugu","family":"Nagao","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Metabolism and Nephrology, Graduate School of Medicine, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruki","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Metabolism and Nephrology, Graduate School of Medicine, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Etsuya","family":"Fukunaga","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Metabolism and Nephrology, Graduate School of Medicine, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0675-444X","authenticated-orcid":false,"given":"Tomoko","family":"Nagamine","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Metabolism and Nephrology, Graduate School of Medicine, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoko","family":"Inagaki","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Metabolism and Nephrology, Graduate School of Medicine, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Izumi","family":"Fukuda","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Metabolism and Nephrology, Graduate School of Medicine, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Iwabu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Metabolism and Nephrology, Graduate School of Medicine, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,6,25]]},"reference":[{"issue":"2","key":"2024112512433118500_lvae081-B1","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med."},{"issue":"4","key":"2024112512433118500_lvae081-B2","doi-asserted-by":"crossref","first-page":"225","DOI":"10.14740\/jocmr3750","article-title":"Adverse effects of immune checkpoint inhibitors (programmed death-1 inhibitors and cytotoxic T-lymphocyte-associated protein-4 inhibitors): results of a retrospective study","volume":"11","author":"Bajwa","year":"2019","journal-title":"J Clin Med Res"},{"issue":"3","key":"2024112512433118500_lvae081-B3","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1055\/a-0843-3366","article-title":"A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors","volume":"51","author":"de Filette","year":"2019","journal-title":"Horm Metab Res"},{"issue":"12","key":"2024112512433118500_lvae081-B4","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1007\/s00125-009-1539-9","article-title":"Differential association of HLA with three subtypes of type 1 diabetes: fulminant, slowly progressive and acute-onset","volume":"52","author":"Kawabata","year":"2009","journal-title":"Diabetologia"},{"issue":"4","key":"2024112512433118500_lvae081-B5","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.2337\/db07-1331","article-title":"HLA DR-DQ haplotypes and genotypes and type 1 diabetes risk analysis of the type 1 diabetes genetics consortium families","volume":"57","author":"Erlich","year":"2008","journal-title":"Diabetes"},{"issue":"2","key":"2024112512433118500_lvae081-B6","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1080\/08820139.2018.1493498","article-title":"Association of HLA-DRB1 and -DQB1 alleles with type 1 (autoimmune) diabetes in African Arabs: systematic review and meta-analysis","volume":"48","author":"Hajjej","year":"2019","journal-title":"Immunol Invest"},{"issue":"4","key":"2024112512433118500_lvae081-B7","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s11102-022-01231-1","article-title":"HLA analysis of immune checkpoint inhibitor-induced and idiopathic isolated ACTH deficiency","volume":"25","author":"Ono","year":"2022","journal-title":"Pituitary"},{"issue":"6","key":"2024112512433118500_lvae081-B8","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1111\/cen.14082","article-title":"Comparative analysis of human leucocyte antigen between idiopathic and anti-PD-1 antibody induced isolated adrenocorticotropic hormone deficiency: a pilot study","volume":"91","author":"Inaba","year":"2019","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2024112512433118500_lvae081-B9","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3803\/EnM.2021.1282","article-title":"Human leukocyte antigens and biomarkers in type 1 diabetes Mellitus induced by immune-checkpoint inhibitors","volume":"37","author":"Inaba","year":"2022","journal-title":"Endocrinol Metab"},{"issue":"2","key":"2024112512433118500_lvae081-B10","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s11154-020-09618-w","article-title":"Diabetes mellitus induced by immune checkpoint inhibitors: type 1 diabetes variant or new clinical entity? Review of the literature","volume":"22","author":"Lo Preiato","year":"2021","journal-title":"Rev Endocr Metab Disord"},{"issue":"3","key":"2024112512433118500_lvae081-B11","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s12020-023-03394-8","article-title":"Clinical characteristics and human leukocyte antigens in patients with immune checkpoint inhibitor-induced type 1 diabetes and pituitary dysfunction: a single center prospective study","volume":"81","author":"Hara","year":"2023","journal-title":"Endocrine"},{"issue":"9","key":"2024112512433118500_lvae081-B12","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1210\/jc.2018-00728","article-title":"Programmed cell death-1 inhibitor-induced type 1 diabetes Mellitus","volume":"103","author":"Clotman","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"2024112512433118500_lvae081-B13","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ejca.2020.02.049","article-title":"Human leucocyte antigen DR15, a possible predictive marker for immune checkpoint inhibitor\u2013induced secondary adrenal insufficiency","volume":"130","author":"Yano","year":"2020","journal-title":"Eur J Cancer"},{"issue":"7","key":"2024112512433118500_lvae081-B14","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.3201\/eid2807.220127","article-title":"Type 1 diabetes Mellitus associated with nivolumab after second SARS-CoV-2 vaccination, Japan","volume":"28","author":"Sato","year":"2022","journal-title":"Emerg Infect Dis"},{"issue":"8","key":"2024112512433118500_lvae081-B15","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1111\/jdi.13807","article-title":"Two cases with fulminant type 1 diabetes that developed long after cessation of immune checkpoint inhibitor treatment","volume":"13","author":"Hatayama","year":"2022","journal-title":"J Diabetes Investig"},{"key":"2024112512433118500_lvae081-B16","first-page":"672","article-title":"A case of type 1 diabetes Mellitus in a patient with type 2 diabetes Mellitus during treatment with pembrolizumab","volume":"65","author":"Shimizu","year":"2022","journal-title":"J Japan Diabetes Soc"},{"key":"2024112512433118500_lvae081-B17","first-page":"169","article-title":"A case of fulminant type 1 diabetes developed after the initiation of nivolumab therapy: including an analysis with systematic review","volume":"64","author":"Asanuma","year":"2021","journal-title":"J Japan Diabetes Soc"},{"issue":"2","key":"2024112512433118500_lvae081-B18","doi-asserted-by":"crossref","first-page":"158","DOI":"10.2958\/suizo.36.158","article-title":"Acute-onset type 1 diabetes mellitus developing after administration of pembrolizumab: a case report","volume":"36","author":"Sakamoto","year":"2021","journal-title":"Suizo"},{"key":"2024112512433118500_lvae081-B19","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1507\/endocrj.EJ20-0769","article-title":"Efficacies of programmed cell death 1 ligand 1 blockade in non-small cell lung cancer patients with acquired resistance to prior programmed cell death 1 inhibitor and development of diabetic ketoacidosis caused by two different etiologies: a retrospective case series","volume":"68","author":"Ishi","year":"2021","journal-title":"Endocr J"},{"key":"2024112512433118500_lvae081-B20","first-page":"746","article-title":"Acute exacerbation of type 1 diabetes and transient thyrotoxicosis around the same time after anti-PD-1 antibody administration in a lung cancer patient","volume":"63","author":"Ishino","year":"2020","journal-title":"J Japan Diabetes Soc"},{"key":"2024112512433118500_lvae081-B21","first-page":"811","article-title":"A case of acute onset type 1 diabetes diagnosed after the development of diabetic ketoacidosis following the administration of atezolizumab","volume":"63","author":"Inoue","year":"2020","journal-title":"J Japan Diabetes Soc"},{"issue":"1","key":"2024112512433118500_lvae081-B22","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/jdi.13099","article-title":"Anti-programmed death ligand 1 therapy-induced type 1 diabetes presenting with multiple islet-related autoantibodies","volume":"11","author":"Honoki","year":"2020","journal-title":"J Diabetes Investig"},{"issue":"2","key":"2024112512433118500_lvae081-B23","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s13340-020-00459-1","article-title":"Case of slowly progressive type 1 diabetes mellitus with drastically reduced insulin secretory capacity after immune checkpoint inhibitor treatment for advanced renal cell carcinoma","volume":"12","author":"Yamaguchi","year":"2021","journal-title":"Diabetol Int"},{"issue":"19","key":"2024112512433118500_lvae081-B24","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.2169\/internalmedicine.2780-19","article-title":"A patient with nivolumab-related fulminant type 1 diabetes mellitus whose serum C-peptide level was preserved at the initial detection of hyperglycemia","volume":"58","author":"Yamamoto","year":"2019","journal-title":"Int Med"},{"issue":"9","key":"2024112512433118500_lvae081-B25","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00262-018-2203-3","article-title":"Fulminant onset of insulin-dependent diabetes with positive anti-GAD antibody titers during treatment with nivolumab in a patient with NSCLC","volume":"67","author":"Matsuura","year":"2018","journal-title":"Cancer Immunol Immunother."},{"key":"2024112512433118500_lvae081-B26","first-page":"237","article-title":"A case of fulminant type 1 diabetes mellitus developed after the administration of nibormab, a immune checkpoint inhibitor","volume":"60","author":"Asai","year":"2017","journal-title":"J Japan Diabetes Soc"},{"issue":"6","key":"2024112512433118500_lvae081-B27","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/jdi.12627","article-title":"Acute-onset type 1 diabetes mellitus caused by nivolumab in a patient with advanced pulmonary adenocarcinoma","volume":"8","author":"Kumagai","year":"2017","journal-title":"J Diabetes Investig"},{"issue":"2","key":"2024112512433118500_lvae081-B28","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1620\/tjem.239.155","article-title":"Nivolumab, an anti-programmed cell death-1 antibody, induces fulminant type 1 diabetes","volume":"239","author":"Miyoshi","year":"2016","journal-title":"Tohoku J Exp Med"},{"issue":"4","key":"2024112512433118500_lvae081-B29","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1507\/endocrj.EJ18-0328","article-title":"Fulminant type 1 diabetes associated with isolated ACTH deficiency induced by anti-programmed cell death 1 antibody\u2014insight into the pathogenesis of autoimmune endocrinopathy\u2014","volume":"66","author":"Okahata","year":"2019","journal-title":"Endocr J"},{"key":"2024112512433118500_lvae081-B30","first-page":"521","article-title":"A case of type 1 diabetes mellitus developed hypopituitarism at around the same time after treatment with pembrolizumab","volume":"63","author":"Ueda","year":"2020","journal-title":"J Japan Diabetes Soc"},{"key":"2024112512433118500_lvae081-B31","first-page":"529","article-title":"A case of fulminant type 1 diabetes manifested after the treatment of adrenocortical insufficiency secondary to anti-programmed cell death-1 therapy","volume":"64","author":"Kumagai","year":"2021","journal-title":"J Japan Diabetes Soc"},{"key":"2024112512433118500_lvae081-B32","first-page":"254","article-title":"A case of fulminant type 1 diabetes Mellitus, secondary adrenal insufficiency, and hypothyroidism after pembrolizumab administration","volume":"66","author":"Tanaka","year":"2023","journal-title":"J Japan Diabetes Soc"},{"key":"2024112512433118500_lvae081-B33","doi-asserted-by":"crossref","first-page":"e30398","DOI":"10.1097\/MD.0000000000030398","article-title":"Type 1 diabetes associated with immune checkpoint inhibitors for malignant melanoma: a case report and review of 8 cases","volume":"101","author":"Ishiguro","year":"2022","journal-title":"Med (Baltimore)"},{"issue":"3","key":"2024112512433118500_lvae081-B34","doi-asserted-by":"crossref","first-page":"bvad002","DOI":"10.1210\/jendso\/bvad002","article-title":"Combined hypophysitis and type 1 diabetes Mellitus related to immune checkpoint inhibitors","volume":"7","author":"Fujita","year":"2023","journal-title":"J Endocr Soc"},{"key":"2024112512433118500_lvae081-B35","author":"HLA LABORATORY, Japan INC"},{"issue":"4","key":"2024112512433118500_lvae081-B36","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/tan.12536","article-title":"Determination of HLA-A, -C, -B, -DRB1 allele and haplotype frequency in Japanese population based on family study","volume":"85","author":"Ikeda","year":"2015","journal-title":"Tissue Antigens"},{"issue":"1","key":"2024112512433118500_lvae081-B37","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/jdi.12119","article-title":"Diagnostic criteria for acute-onset type 1 diabetes mellitus (2012): report of the committee of Japan diabetes society on the research of fulminant and acute-onset type 1 diabetes mellitus","volume":"5","author":"Kawasaki","year":"2014","journal-title":"J Diabetes Investig"},{"issue":"6","key":"2024112512433118500_lvae081-B38","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/jdi.12024","article-title":"Report of the committee of the Japan diabetes society on the research of fulminant and acute-onset type 1 diabetes Mellitus: new diagnostic criteria of fulminant type 1 diabetes mellitus","volume":"3","author":"Imagawa","year":"2012","journal-title":"J Diabetes Investig"},{"issue":"1","key":"2024112512433118500_lvae081-B39","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1530\/EJE-07-0066","article-title":"A simple diagnostic test using GH-releasing peptide-2 in adult GH deficiency","volume":"157","author":"Chihara","year":"2007","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2024112512433118500_lvae081-B40","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s13340-018-0362-2","article-title":"Characteristics and clinical course of type 1 diabetes mellitus related to anti-programmed cell death-1 therapy","volume":"10","author":"Baden","year":"2019","journal-title":"Diabetol Int"},{"key":"2024112512433118500_lvae081-B41","doi-asserted-by":"crossref","first-page":"1164120","DOI":"10.3389\/fimmu.2023.1164120","article-title":"Clinical and HLA genotype analysis of immune checkpoint inhibitor-associated diabetes mellitus: a single-center case series from China","volume":"14","author":"Liu","year":"2023","journal-title":"Front Immunol"},{"issue":"3","key":"2024112512433118500_lvae081-B42","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1530\/EJE-19-0291","article-title":"Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review","volume":"181","author":"De Filette","year":"2019","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2024112512433118500_lvae081-B43","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1084\/jem.20022125","article-title":"The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice","volume":"198","author":"Ansari","year":"2003","journal-title":"J Exp Med"},{"issue":"7","key":"2024112512433118500_lvae081-B44","doi-asserted-by":"crossref","first-page":"e116","DOI":"10.2337\/dc18-2518","article-title":"T-lymphocyte infiltration to islets in the pancreas of a patient who developed type 1 diabetes after administration of immune checkpoint inhibitors","volume":"42","author":"Yoneda","year":"2019","journal-title":"Diabetes Care"},{"issue":"1-2","key":"2024112512433118500_lvae081-B45","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.imlet.2011.05.003","article-title":"Low CTLA-4 expression in CD4 + helper T-cells in patients with fulminant type 1 diabetes","volume":"139","author":"Haseda","year":"2011","journal-title":"Immunol Lett"},{"issue":"4","key":"2024112512433118500_lvae081-B46","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.4049\/jimmunol.0900679","article-title":"Transgenic expression of single-chain anti-CTLA-4 Fv on \u03b2 cells protects nonobese diabetic mice from autoimmune diabetes","volume":"183","author":"Shieh","year":"2009","journal-title":"J Immunol"},{"issue":"2","key":"2024112512433118500_lvae081-B47","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1373\/clinchem.2010.148221","article-title":"Genetics of type 1 diabetes","volume":"57","author":"Steck","year":"2011","journal-title":"Clin Chem"},{"issue":"9","key":"2024112512433118500_lvae081-B48","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.2337\/db13-0094","article-title":"HLA class II genotyping of African American type 1 diabetic patients reveals associations unique to African haplotypes","volume":"62","author":"Noble","year":"2013","journal-title":"Diabetes"},{"issue":"4","key":"2024112512433118500_lvae081-B49","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s13340-020-00468-0","article-title":"Genetics of fulminant type 1 diabetes","volume":"11","author":"Kawabata","year":"2020","journal-title":"Diabetol Int"},{"issue":"4","key":"2024112512433118500_lvae081-B50","doi-asserted-by":"crossref","first-page":"e0154255","DOI":"10.1371\/journal.pone.0154255","article-title":"Human leukocyte antigen and systemic sclerosis in Japanese: the sign of the four independent protective alleles, DRB1 13:02, DRB1 14:06, DQB1 03:01, and DPB1 02:01","volume":"11","author":"Furukawa","year":"2016","journal-title":"PLoS One"},{"issue":"6","key":"2024112512433118500_lvae081-B51","doi-asserted-by":"crossref","first-page":"e99453","DOI":"10.1371\/journal.pone.0099453","article-title":"Protective effect of the HLA-DRB1*13:02 allele in Japanese rheumatoid arthritis patients","volume":"9","author":"Oka","year":"2014","journal-title":"PLoS One"},{"issue":"1-2","key":"2024112512433118500_lvae081-B52","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jaut.2007.11.010","article-title":"The HLA gene complex in thyroid autoimmunity: from epidemiology to etiology","volume":"30","author":"Jacobson","year":"2008","journal-title":"J Autoimmun"},{"issue":"37","key":"2024112512433118500_lvae081-B53","doi-asserted-by":"crossref","first-page":"14034","DOI":"10.1073\/pnas.0806584105","article-title":"Molecular amino acid signatures in the MHC class II peptide-binding pocket predispose to autoimmune thyroiditis in humans and in mice","volume":"105","author":"Menconi","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"2024112512433118500_lvae081-B54","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1089\/thy.2020.0075","article-title":"Immune checkpoint inhibitor-induced thyroiditis is associated with increased intrathyroidal T lymphocyte subpopulations","volume":"30","author":"Kotwal","year":"2020","journal-title":"Thyroid"},{"key":"2024112512433118500_lvae081-B55","author":"e-Stat Portal Site of Official Statistics of Japan","year":"2020"}],"container-title":["European Journal of Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ejendo\/advance-article-pdf\/doi\/10.1093\/ejendo\/lvae081\/58329629\/lvae081.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/191\/1\/9\/60808132\/lvae081.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/191\/1\/9\/60808132\/lvae081.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T12:43:51Z","timestamp":1732538631000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/191\/1\/9\/7698910"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,25]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,7,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ejendo\/lvae081","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,7]]},"published":{"date-parts":[[2024,6,25]]}}}